Cite
Pillet S, Arunachalam PS, Andreani G, et al. Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates. Cell Mol Immunol. 2022;doi: 10.1038/s41423-021-00809-2.
Pillet, S., Arunachalam, P. S., Andreani, G., Golden, N., Fontenot, J., Aye, P. P., Röltgen, K., Lehmicke, G., Gobeil, P., Dubé, C., Trépanier, S., Charland, N., D'Aoust, M. A., Russell-Lodrigue, K., Monjure, C., Blair, R. V., Boyd, S. D., Bohm, R. P., Rappaport, J., Villinger, F., Landry, N., Pulendran, B., & Ward, B. J. (2022). Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates. Cellular & molecular immunology, . https://doi.org/10.1038/s41423-021-00809-2
Pillet, Stéphane, et al. "Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates." Cellular & molecular immunology vol. (2022). doi: https://doi.org/10.1038/s41423-021-00809-2
Pillet S, Arunachalam PS, Andreani G, Golden N, Fontenot J, Aye PP, Röltgen K, Lehmicke G, Gobeil P, Dubé C, Trépanier S, Charland N, D'Aoust MA, Russell-Lodrigue K, Monjure C, Blair RV, Boyd SD, Bohm RP, Rappaport J, Villinger F, Landry N, Pulendran B, Ward BJ. Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates. Cell Mol Immunol. 2022 Jan 05; doi: 10.1038/s41423-021-00809-2. Epub 2022 Jan 05. PMID: 34983950.
Copy
Download .nbib